VACC vs. LPTX, LFVN, BRNS, BYSI, MRNS, IFRX, ALRN, TPST, CNTB, and AFMD
Should you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Leap Therapeutics (LPTX), LifeVantage (LFVN), Barinthus Biotherapeutics (BRNS), BeyondSpring (BYSI), Marinus Pharmaceuticals (MRNS), InflaRx (IFRX), Aileron Therapeutics (ALRN), Tempest Therapeutics (TPST), Connect Biopharma (CNTB), and Affimed (AFMD). These companies are all part of the "pharmaceutical preparations" industry.
Leap Therapeutics (NASDAQ:LPTX) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, community ranking, valuation, earnings and institutional ownership.
In the previous week, Leap Therapeutics had 3 more articles in the media than Vaccitech. MarketBeat recorded 3 mentions for Leap Therapeutics and 0 mentions for Vaccitech. Vaccitech's average media sentiment score of 0.00 equaled Leap Therapeutics'average media sentiment score.
Leap Therapeutics has a net margin of 0.00% compared to Leap Therapeutics' net margin of -409.18%. Leap Therapeutics' return on equity of -23.41% beat Vaccitech's return on equity.
Leap Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500.
30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 26.1% of Vaccitech shares are held by institutional investors. 11.3% of Leap Therapeutics shares are held by company insiders. Comparatively, 6.0% of Vaccitech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Vaccitech has higher revenue and earnings than Leap Therapeutics. Vaccitech is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
Leap Therapeutics received 272 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 68.65% of users gave Leap Therapeutics an outperform vote.
Leap Therapeutics currently has a consensus target price of $11.38, indicating a potential upside of 312.14%. Vaccitech has a consensus target price of $7.63, indicating a potential upside of 235.90%. Given Vaccitech's stronger consensus rating and higher probable upside, equities analysts plainly believe Leap Therapeutics is more favorable than Vaccitech.
Summary
Leap Therapeutics beats Vaccitech on 11 of the 17 factors compared between the two stocks.
Get Vaccitech News Delivered to You Automatically
Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaccitech Competitors List
Related Companies and Tools
